Latest Half Year Results News

Ramsay Health Care’s half-year results reveal a dramatic net profit rebound, driven by prior year impairments and solid growth in Australia and Europe. The company also announced a strategic acquisition and a proposed share distribution.

Control Bionics Limited reported a sharp increase in losses for the half-year ending December 2025, coinciding with its acquisition of full control over Neuro Elite Athletics, LLC. The company faces ongoing financial challenges despite no dividends being declared.

Beforepay Group Limited reported a robust half-year performance with revenues climbing 18.7% and profit after tax nearly doubling, driven by growth in lending volumes and strategic expansion of its Carrington Labs credit analytics business.

Babylon Pump & Power reported a $7.16 million loss for H1 FY26, weighed down by acquisition-related expenses and an impairment charge, while its rental segment soared post-acquisitions.

Vault Minerals has delivered a robust half-year result with a 44% jump in EBITDA and declared its first-ever dividend, signalling confidence in its growth and cash flow outlook.

ZMM has reported a remarkable 253% increase in revenue for the half-year ending December 2025, yet still recorded a net loss of $1.078 million amid concerns over its financial sustainability.

Experience Co Limited reported a 5% increase in sales revenue to $67.2 million for 1H26, with underlying EBITDA steady at $10.5 million despite operational challenges. The company is streamlining its portfolio by selling Wild Bush Luxury and focusing on scalable adventure experiences.

Kingsgate Consolidated Limited has reported a spectacular half-year performance with a 3,491% jump in net profit and a doubling of revenue, driven by higher gold and silver production. The company also declared its first interim dividend in years, signalling confidence in its growth trajectory.

State Street SPDR Core Equity ETFs have reported consistent half-year results for the period ending 31 December 2025, maintaining alignment with their benchmark indices and continuing to provide reliable distributions to unitholders.

TPC Consolidated Limited reported a 4.1% revenue increase to $103.6 million and a 62% jump in underlying EBITDA for the half-year ended December 2025, while the proposed acquisition scheme faces regulatory hurdles.

Cleo Diagnostics reported a 53% drop in revenues and a slight increase in net loss to $1.98 million for H1 2025, while progressing its pivotal FDA clinical trial for an ovarian cancer blood test with strong regulatory and commercial milestones.

Acorn Capital Investment Fund Limited has reported a remarkable half-year performance for the period ending 31 December 2025, with revenue and profit soaring over 300%. The fund also declared a fully franked interim dividend of 3.5 cents per share, signalling confidence in its investment strategy.